Concomitant Radiochemotherapy plus Surgery in Locally Advanced Cervical Cancer: Update of Clinical Outcome and Cyclooxygenase-2 as Predictor of Treatment Susceptibility
- 1 September 2004
- journal article
- research article
- Published by S. Karger AG in Oncology
- Vol. 67 (2) , 103-111
- https://doi.org/10.1159/000080995
Abstract
Objective: We have updated our findings on the efficacy of concomitant radiochemotherapy plus radical surgery in a larger series of patients (n = 54) with locally advanced cervical cancer (LACC). We also investigated the role of cyclooxygenase-2 (COX-2) in this clinical setting. Methods: Radiotherapy was administered to the whole pelvic region (1.8 Gy/day, totaling 39.6 Gy) in combination with cisplatin (20 mg/m2) and 5-fluorouracil (1,000 mg/m2) (both on days 1–4 and 27–30). Radical surgery was performed 5–6 weeks after the end of treatment. Results: A clinical complete or partial response was observed in all 53 evaluable patients (75.5 and 24.5%, respectively). At pathological examination, 23 of 51 patients (45.1%) undergoing radical surgery showed complete response to treatment, 18 patients (35.3%) only had microscopic residual disease, 6 patients (11.7%) had a partial response and 4 (7.8%) had no change in their disease. When logistic regression was applied, the FIGO stage (χ2 = 5.28, p = 0.021) and tumor to stroma COX-2 ratio (χ2 = 4.72, p = 0.029) retained an independent role in the prediction of the pathologic response to treatment. The 3-year disease-free survival (DFS) was 75.2%, with local relapse-free survival of 86.2% and metastasis-free interval of 89.9% at 3 years. Cases with a high COX-2 ratio showed a shorter DFS than cases with a low COX-2 ratio (p = 0.016). A direct association was shown between COX-2 ratio values and risk of recurrence, as assessed by Cox analysis using COX-2 ratio values as a continuous covariate (χ2 = 3.94, p = 0.047). Conclusion: This study confirms the possibility of achieving a very high rate of pathological responses in LACC patients administered chemoradiation plus surgery (3-year DFS 75.2%). Moreover, COX-2 status may play a role in the prognostic characterization and prediction of tumor response.Keywords
This publication has 15 references indexed in Scilit:
- Overexpression of cyclooxygenase‐2 is associated with a poor prognosis in patients with squamous cell carcinoma of the uterine cervix treated with radiation and concurrent chemotherapyCancer, 2002
- Phase III Trial Comparing Radical Radiotherapy With and Without Cisplatin Chemotherapy in Patients With Advanced Squamous Cell Cancer of the CervixJournal of Clinical Oncology, 2002
- Increased Cyclooxygenase-2 Expression Is Associated With Chemotherapy Resistance and Poor Survival in Cervical Cancer PatientsJournal of Clinical Oncology, 2002
- Neoadjuvant Chemotherapy and Radical Surgery Versus Exclusive Radiotherapy in Locally Advanced Squamous Cell Cervical Cancer: Results From the Italian Multicenter Randomized StudyJournal of Clinical Oncology, 2002
- Is There a Place for a Less Extensive Radical Surgery in Locally Advanced Cervical Cancer Patients?Gynecologic Oncology, 2001
- Phase I–II Trial of Preoperative Chemoradiation in Locally Advanced Cervical CarcinomaGynecologic Oncology, 2000
- Pilot Study of Concurrent Cisplatin, 5-Fluorouracil, and External Beam Radiotherapy Prior to Radical Surgery +/− Intraoperative Electron Beam Radiotherapy in Locally Advanced Cervical CancerGynecologic Oncology, 1999
- Concurrent Cisplatin-Based Radiotherapy and Chemotherapy for Locally Advanced Cervical CancerNew England Journal of Medicine, 1999
- Pelvic Radiation with Concurrent Chemotherapy Compared with Pelvic and Para-Aortic Radiation for High-Risk Cervical CancerNew England Journal of Medicine, 1999
- Concomitant Chemoradiation prior to Surgery in the Treatment of Advanced Cervical CarcinomaGynecologic Oncology, 1994